Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629196 | 0.87 | ALDH1A1 (0.62) | MAPTNPSR1RXFP1HSD11B1ALDH1A1 | |
| SCHEMBL26769391 | 0.85 | PDE2A (0.65) | PDE2AMAPTNPSR1RXFP1PKLR | |
| SCHEMBL26766526 | 0.85 | ALDH1A1 (0.52) | MAPTNPSR1RXFP1HSD11B1ALDH1A1 | |
| SCHEMBL17634253 | 0.85 | MAPT (0.72) | MAPTRXFP1HSD11B1ALDH1A1KDM4E | |
| SCHEMBL30629155 | 0.85 | MAPT (0.72) | MAPTRXFP1HSD11B1ALDH1A1KDM4E | |
| SCHEMBL30809616 | 0.85 | MAPT (0.72) | MAPTRXFP1HSD11B1ALDH1A1KDM4E | |
| SCHEMBL26769914 | 0.80 | MAPT (0.68) | PDE2AMAPTNPSR1RXFP1PKLR | |
| SCHEMBL26766600 | 0.79 | MAPT (0.71) | PDE2AMAPTNPSR1RXFP1PKLR | |
| SCHEMBL10847170 | 0.79 | HPGD (0.72) | HSD11B1MAOBHPGDSTSMAOA | |
| SCHEMBL29853647 | 0.78 | MAPT (0.89) | PDE2AMAPTNPSR1RXFP1PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | PDE2A 1089/4885MAPT 217/4885NPSR1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.